Cyclerion Therapeutics, Inc. (CYCN)

NASDAQ: CYCN · IEX Real-Time Price · USD
0.876
-0.024 (-2.63%)
At close: Dec 2, 2022 4:00 PM
0.870
-0.006 (-0.72%)
Pre-market: Dec 5, 2022 7:04 AM EST
-2.63%
Market Cap 38.31M
Revenue (ttm) 1.55M
Net Income (ttm) -47.64M
Shares Out 43.49M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 89,364
Open 0.876
Previous Close 0.9
Day's Range 0.86 - 0.905
52-Week Range 0.35 - 2.05
Beta 1.75
Analysts Buy
Price Target 4.08 (+365.6%)
Earnings Date Nov 8, 2022

About CYCN

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also ... [Read more]

Industry Biotechnology
Employees 32
Stock Exchange NASDAQ
Ticker Symbol CYCN
Full Company Profile

Financial Performance

In 2021, CYCN's revenue was $3.94 million, an increase of 71.69% compared to the previous year's $2.30 million. Losses were -$51.65 million, -33.62% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CYCN stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 365.59% from the latest price.

Price Target
$4.08
(365.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and dis...

1 week ago - GlobeNewsWire

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases

1 month ago - GlobeNewsWire

Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates

Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associat...

3 months ago - GlobeNewsWire

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Asso...

Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care

4 months ago - GlobeNewsWire

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Renowned neuroscience leader to further long-term clinical research strategy and external collaborations Renowned neuroscience leader to further long-term clinical research strategy and external collabo...

4 months ago - GlobeNewsWire

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochon...

Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients

5 months ago - GlobeNewsWire

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foun...

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients

5 months ago - GlobeNewsWire

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in preclin...

5 months ago - Benzinga

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mito...

CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency

5 months ago - GlobeNewsWire

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Me...

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity

5 months ago - GlobeNewsWire

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF M...

Topline results to be shared during the clinical trial update platform session

5 months ago - GlobeNewsWire

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Characterizing the novel neuropharmacology of CY6463's NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking stu...

7 months ago - GlobeNewsWire

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022

9 months ago - GlobeNewsWire

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Collaboration to identify patient-selection biomarkers for Cyclerion's investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment Collaboration to id...

9 months ago - GlobeNewsWire

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Va...

Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition

10 months ago - GlobeNewsWire

Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)

The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...

11 months ago - Zacks Investment Research

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive func...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS)

1 year ago - GlobeNewsWire

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Truist analyst Joon Lee has initiated coverage of Cyclerion Therapeutics Inc (NASDAQ:CYCN) with a Buy rating and price target of $14, suggesting a massive 374% upside. The development of drugs targeting...

1 year ago - Benzinga

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant s...

Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cog...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessm...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive imp...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Di...

Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting poten...

1 year ago - GlobeNewsWire

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies.  This collaboration is expected to identify disease-relevant biomarkers to...

1 year ago - Benzinga